Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-κB/Snail/YY1/RKIP circuitry

Nitric Oxide - Biology and Chemistry

Volumn 24, Issue 1, 2011, Pages 1-7

  Bonavida, Benjamin ^a   Baritaki, Stavroula ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; EMT; NF B Snail YY1 RKIP circuitry; Resistance; Therapeutic targets

Indexed keywords

1 [2 (2 AMINOETHYL) N (2 AMMONIO ETHYL) AMINO] DIAZEN 1 IUM 1,2 DIOLATE; CISPLATIN; CYTOTOXIC AGENT; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; LIGAND; NITRIC OXIDE DONOR; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RAF PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL FUNCTION; CELL SURVIVAL; DOWN REGULATION; DRUG CYTOTOXICITY; EPITHELIUM; HUMAN; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; IN VIVO STUDY; MESENCHYME; METASTASIS; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; STIMULUS; TUMOR CELL; TUMOR GENE; TUMOR GROWTH; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; NEOPLASMS; NF-KAPPA B; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; YY1 TRANSCRIPTION FACTOR;

GASTROPODA;

EID: 79251609206     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2010.10.001     Document Type: Review

References (65)

1. A. Singh, and J. Settleman EMT, cancer stem cells and drug resistance. an emerging axis of evil in the war on cancer Oncogene 29 2010 4741 4751
2. D.S. Tan, M. Gerlinger, B.T. Teh, and C. Swanton Anti-cancer drug resistance. Understanding the mechanisms through the use of integrative genomics and functional RNA interference Eur. J. Cancer 46 2010 2143 2144
3. J.C. Reed Dysregulation of apoptosis in cancer J. Clin. Oncol. 17 1999 2941 2953
4. S. Raguz, and E. Yague Resistance to chemotherapy: new treatments and novel insights into an old problem Br. J. Cancer 99 2008 387 391
5. M.A. Shah, and G.K. Schwartz Cell cycle-mediated drug resistance. an emerging concept in cancer therapy Clin. Cancer Res. 7 2001 2168 2181
6. K. DeClerck, and R.C. Elble The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy Front Biosci. 15 2010 213 225
7. H. Acloque, J.P. Thiery, and M.A. Nieto The physiology and pathology of the EMT Meeting on the epithelial-mesenchymal transition EMBO Rep. 9 2008 322 326
8. J.P. Thiery, and J.P. Sleeman Complex networks orchestrate epithelial-mesenchymal transitions Nat. Rev. Mol. Cell Biol. 7 2006 131 142
9. S. Baritaki, K. Yeung, M. Palladino, J. Berenson, and B. Bonavida Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization Cancer Res. 69 2009 8376 8385
10. S. Huerta-Yepez, M. Vega, A. Jazirehi, H. Garban, F. Hongo, G. Cheng, and B. Bonavida Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression Oncogene 23 2004 4993 5003
11. S. Huerta-Yepez, M. Vega, S.E. Escoto-Chavez, B. Murdock, T. Sakai, S. Baritaki, and B. Bonavida Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1 Nitric Oxide 20 2009 39 52
12. A.R. Jazirehi, M.I. Vega, D. Chatterjee, L. Goodglick, and B. Bonavida Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab Cancer Res. 64 2004 7117 7126
13. M.I. Vega, A.R. Jazirehi, S. Huerta-Yepez, and B. Bonavida Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively J. Immunol. 175 2005 2174 2183
14. Y. Lin, L. Bai, W. Chen, and S. Xu The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy Expert Opin. Ther. Targets 14 2010 45 55
15. H. Wang, E. Hertlein, N. Bakkar, H. Sun, S. Acharyya, J. Wang, M. Carathers, R. Davuluri, and D.C. Guttridge NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes Mol. Cell. Biol. 27 2007 4374 4387
16. L. Kleinberg, and B. Davidson Cell survival and apoptosis-related molecules in cancer cells in effusions: a comprehensive review Diagn. Cytopathol. 37 2009 613 624
17. C. Min, S.F. Eddy, D.H. Sherr, and G.E. Sonenshein NF-kappaB and epithelial to mesenchymal transition of cancer J. Cell. Biochem. 104 2008 733 744
18. M.A. Huber, N. Azoitei, B. Baumann, S. Grunert, A. Sommer, H. Pehamberger, N. Kraut, H. Beug, and T. Wirth NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression J. Clin. Invest. 114 2004 569 581
19. S.R. Shin, N. Sanchez-Velar, D.H. Sherr, and G.E. Sonenshein 7, 12-dimethylbenz(a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-kappaB Cancer Res. 66 2006 2570 2575
20. S. Julien, I. Puig, E. Caretti, J. Bonaventure, L. Nelles, F. van Roy, C. Dargemont, A.G. de Herreros, A. Bellacosa, and L. Larue Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition Oncogene 26 2007 7445 7456
21. S. Beach, H. Tang, S. Park, A.S. Dhillon, E.T. Keller, W. Kolch, and K.C. Yeung Snail is a repressor of RKIP transcription in metastatic prostate cancer cells Oncogene 27 2008 2243 2248
22. A. Cano, M.A. Perez-Moreno, I. Rodrigo, A. Locascio, M.J. Blanco, M.G. Del Barrio, F. Portillo, and M.A. Nieto The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression Nat. Cell Biol. 2 2000 76 83
23. A. Katsman, K. Umezawa, and B. Bonavida Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent Drug Resist. Updat. 10 2007 1 12
24. M. Brown, J. Cohen, P. Arun, Z. Chen, and C. Van Waes NF-kappaB in carcinoma therapy and prevention Expert. Opin. Ther. Targets 12 2008 1109 1122
25. D.J. McConkey, and K. Zhu Mechanisms of proteasome inhibitor action and resistance in cancer Drug Resist. Updat. 11 2008 164 179
26. V. Baud, and M. Karin Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls Nat. Rev. Drug Discovery 8 2009 33 40
27. F. Li, and G. Sethi Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy Biochim. Biophys. Acta 1805 2010 167 180
28. C. Mauro, F. Zazzeroni, S. Papa, C. Bubici, and G. Franzoso The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity Methods Mol. Biol. 512 2009 169 207
29. L. Zhang, W. Chen, and X. Li A novel anticancer effect of butein: inhibition of invasion through the ERK1/2 and NF-kappa B signaling pathways in bladder cancer cells FEBS Lett. 582 2008 1821 1828
30. K. Tozawa, S. Sakurada, K. Kohri, and T. Okamoto Effects of anti-nuclear factor kappa B reagents in blocking adhesion of human cancer cells to vascular endothelial cells Cancer Res. 55 1995 4162 4167
31. S. Baritaki, A. Chapman, K. Yeung, D.A. Spandidos, M. Palladino, and B. Bonavida Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction Oncogene 28 2009 3573 3585
32. S. Baritaki, E. Suzuki, K. Umezawa, D.A. Spandidos, J. Berenson, T.R. Daniels, M.L. Penichet, A.R. Jazirehi, M. Palladino, and B. Bonavida Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells J. Immunol. 180 2008 6199 6210
33. S. Baritaki, A. Katsman, D. Chatterjee, K.C. Yeung, D.A. Spandidos, and B. Bonavida Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation J. Immunol. 179 2007 5441 5453
34. Y. Wu, and B.P. Zhou Snail: More than EMT Cell Adh. Migr. 4 2010 199 203
35. M.A. Nieto The snail superfamily of zinc-finger transcription factors Nat. Rev. Mol. Cell Biol. 3 2002 155 166
36. M.B. Palmer, P. Majumder, J.C. Cooper, H. Yoon, P.A. Wade, and J.M. Boss Yin yang 1 regulates the expression of snail through a distal enhancer Mol. Cancer Res. 7 2009 221 229
37. D. Olmeda, G. Moreno-Bueno, J.M. Flores, A. Fabra, F. Portillo, and A. Cano SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells Cancer Res. 67 2007 11721 11731
38. S. Gordon, G. Akopyan, H. Garban, and B. Bonavida Transcription factor YY1: structure, function, and therapeutic implications in cancer biology Oncogene 25 2006 1125 1142
39. J. Guo, X. Lin, M.A. Williams, Q. Hamid, and S.N. Georas Yin-Yang 1 regulates effector cytokine gene expression and T(H)2 immune responses J. Allergy Clin. Immunol. 122 2008 195 201
40. J. Ye, H.A. Young, X. Zhang, V. Castranova, V. Vallyathan, and X. Shi Regulation of a cell type-specific silencer in the human interleukin-3 gene promoter by the transcription factor YY1 and an AP2 sequence-recognizing factor J. Biol. Chem. 274 1999 26661 26667
41. J. Ye, X. Zhang, and Z. Dong Characterization of the human granulocyte-macrophage colony-stimulating factor gene promoter: an AP1 complex and an Sp1-related complex transactivate the promoter activity that is suppressed by a YY1 complex Mol. Cell. Biol. 16 1996 157 167
42. H.J. Garban, and B. Bonavida Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells J. Immunol. 167 2001 75 81
43. S. Baritaki, S. Huerta-Yepez, T. Sakai, D.A. Spandidos, and B. Bonavida Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1 Mol. Cancer Ther. 6 2007 1387 1399
44. A.E. Granovsky, and M.R. Rosner Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor Cell Res. 18 2008 452 457
45. K. Yeung, T. Seitz, S. Li, P. Janosch, B. McFerran, C. Kaiser, F. Fee, K.D. Katsanakis, D.W. Rose, H. Mischak, J.M. Sedivy, and W. Kolch Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP Nature 401 1999 173 177
46. K.C. Yeung, D.W. Rose, A.S. Dhillon, D. Yaros, M. Gustafsson, D. Chatterjee, B. McFerran, J. Wyche, W. Kolch, and J.M. Sedivy Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation Mol. Cell. Biol. 21 2001 7207 7217
47. H. Tang, S. Park, S.C. Sun, R. Trumbly, G. Ren, E. Tsung, and K.C. Yeung RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex FEBS Lett. 584 2010 662 668
48. K. Lorenz, M.J. Lohse, and U. Quitterer Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2 Nature 426 2003 574 579
49. D. Chatterjee, Y. Bai, Z. Wang, S. Beach, S. Mott, R. Roy, C. Braastad, Y. Sun, A. Mukhopadhyay, B.B. Aggarwal, J. Darnowski, P. Pantazis, J. Wyche, Z. Fu, Y. Kitagwa, E.T. Keller, J.M. Sedivy, and K.C. Yeung RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis J. Biol. Chem. 279 2004 17515 17523
50. Z. Fu, Y. Kitagawa, R. Shen, R. Shah, R. Mehra, D. Rhodes, P.J. Keller, A. Mizokami, R. Dunn, A.M. Chinnaiyan, Z. Yao, and E.T. Keller Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer Prostate 66 2006 248 256
51. S. Hagan, F. Al-Mulla, E. Mallon, K. Oien, R. Ferrier, B. Gusterson, J.J. Garcia, and W. Kolch Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis Clin. Cancer Res. 11 2005 7392 7397
52. F. Al-Mulla, S. Hagan, A.I. Behbehani, M.S. Bitar, S.S. George, J.J. Going, J.J. Garcia, L. Scott, N. Fyfe, G.I. Murray, and W. Kolch Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients J. Clin. Oncol. 24 2006 5672 5679
53. M.M. Schuierer, F. Bataille, S. Hagan, W. Kolch, and A.K. Bosserhoff Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines Cancer Res. 64 2004 5186 5192
54. Z. Fu, P.C. Smith, L. Zhang, M.A. Rubin, R.L. Dunn, Z. Yao, and E.T. Keller Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis J. Natl Cancer Inst. 95 2003 878 889
55. P. Minoo, I. Zlobec, K. Baker, L. Tornillo, L. Terracciano, J.R. Jass, and A. Lugli Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer Am. J. Clin. Pathol. 127 2007 820 827
56. D. Wink, L. Ridnour, S. Hussain, and C. Harris The reemergence of nitric oxide and cancer Nitric Oxide 19 2008 65 67
57. F. Hongo, H. Garban, S. Huerta-Yepez, M. Vega, A.R. Jazirehi, Y. Mizutani, T. Miki, and B. Bonavida Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation Biochem. Biophys. Res. Commun. 336 2005 692 701
58. D.J. Smith, D. Chakravarthy, S. Pulfer, M.L. Simmons, J.A. Hrabie, M.L. Citro, J.E. Saavedra, K.M. Davies, T.C. Hutsell, D.L. Mooradian, S.R. Hanson, and L.K. Keefer Nitric oxide-releasing polymers containing the [N(O)NO]-group J. Med. Chem. 39 1996 1148 1156
59. L.K. Keefer, R.W. Nims, K.M. Davies, and D.A. Wink NONOates (1-substituted diazen-1-ium-1, 2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms Methods Enzymol. 268 1996 281 293
60. M. Kavdia, and R.S. Lewis Nitric oxide delivery in stagnant systems via nitric oxide donors: a mathematical model Chem. Res. Toxicol. 16 2003 7 14
61. J.G. Diodati, A.A. Quyyumi, N. Hussain, and L.K. Keefer Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: antiplatelet effect Thromb. Haemost. 70 1993 654 658
62. V.G. Nielsen Nitric oxide decreases coagulation protein function in rabbits as assessed by thromboelastography Anesth. Analg. 92 2001 320 323
63. J. Suh, and A.B. Rabson NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J. Cell. Biochem. 91 2004 100 117
64. H. Yasuda Solid tumor physiology and hypoxia-induced chemo/radio- resistance. Novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer Nitric Oxide 19 2008 205 216
65. D.R. Siemens Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer Urology 74 2009 878 883